We're going to get started. Thank you, everyone, for joining us here in Berlin, and there are many more of you that are online. Welcome to the solid tumor update that we're having at ESMO 2025. We're ...
Professional antigen-presenting cells—monocytes and macrophages—engulf these proteins, digest them into short peptide ...
Phase I Clinical Trial Evaluating Safety, Tolerability, and Early Activity of Exarafenib (KIN-2787), a Highly Selective Pan-RAF Inhibitor, in BRAF-Altered Solid Tumors or NRAS-Mutant Melanoma PD-L1 ...
Predictive value of the triglyceride-glucose index for the efficacy of immunotherapy in patients with advanced NSCLC: A retrospective study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
Morning Overview on MSN
The two drugs that just cleared Alzheimer’s plaques in mice already sit in pharmacies as cancer treatments — a shortcut that could reach patients years sooner
In 2012, neuroscientist Gary Landreth and his team at Case Western Reserve University published a finding in Science that ...
The PD-1 receptor, a major immune checkpoint inhibitor whose signaling is the target of multiple blockbuster anticancer drugs, differs functionally between rodents and humans in previously unknown ...
Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results